Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
- 18 February 2022
- journal article
- research article
- Published by Elsevier in Cell Host & Microbe
- Vol. 30 (4) , 485-488.e3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike VariantsNew England Journal of Medicine, 2021
- Neutralizing Activity of BNT162b2-Elicited SerumNew England Journal of Medicine, 2021
- Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited seraNature Medicine, 2021
- Engineering SARS-CoV-2 using a reverse genetic systemNature Protocols, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesNew England Journal of Medicine, 2020
- Spike mutation D614G alters SARS-CoV-2 fitnessNature, 2020
- A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluationNature Communications, 2020
- An Infectious cDNA Clone of SARS-CoV-2Cell Host & Microbe, 2020
- Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to PandemicsScience Translational Medicine, 2013